MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, will host an analyst and institutional investor meeting on Tuesday, June 26, 2018, in New York City from 8:30 a.m. to approximately 10:00 a.m. Eastern Time. The meeting will focus on clinician guest speakers to provide expert perspectives on broad trends in cardiac surgery and electrophysiology, key clinical trials, and the collaboration between physicians to best treat Afib.
- Marc Gillinov, M.D., Chairman of the Department of Thoracic and Cardiovascular Surgery at the Cleveland Clinic and Surgical Director of the Center for Atrial Fibrillation at the Cleveland Clinic
- David De Lurgio, M.D., Electrophysiologist at Emory and the Principal Investigator for AtriCure’s CONVERGE Trial
- Marc Gerdisch, M.D., Chief of Cardiovascular and Thoracic Surgery and Co-Director of the Heart Valve Center and Trial Fibrillation program at Franciscan St. Francis Health
A live audio webcast of the presentation may be accessed by visiting the Investors page of AtriCure’s corporate website at ir.atricure.com. A replay of the presentation will be available for 90 days following the presentation.
AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation System is the first and only medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide, with more than 125,000 implanted to date. For more information, visit AtriCure.com or follow us on Twitter @AtriCure.